Shared Decision Making in PTSD Treatment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe University of Texas Health Science Center at San Antonio

About this trial

The purpose of this research study is to learn about how Shared Decision Making, when used to decide treatment, impacts treatment engagement, retention, and outcomes for active duty military personnel seeking treatment for posttraumatic stress disorder (PTSD).

Shared Decision Making between the service member and the therapists will be used to match patients to 1 of 3 different types of therapy for PTSD: (1) Prolonged Exposure (PE) therapy, (2) Cognitive Processing Therapy (CPT), or (3) Written Exposure Therapy (WET) in 1 of 2 different frequencies: (1) massed (daily) or (2) spaced (weekly).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult active duty military service members aged 18 or older.

Meets diagnostic criteria for PTSD based on the Clinician Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders-5 (CAPS-5).

Disqualifiers

Acute suicidality or homicidality requiring immediate intervention, such as hospitalization.

Moderate to severe brain injury as assessed by the History of Head Injury Form

Severe alcohol consumption patterns as assessed using the Alcohol Use Disorders Identification Test and warranting immediate intervention as determined by clinical judgement.

Experiencing active psychosis or mania as determined by scores on the Prodromal Questionnaire and Mood Disorder Questionnaire in combination with clinical judgement.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Prolonged Exposure Therapy

    Behavioral

    PE is a cognitive-behavioral treatment for PTSD that is typically delivered in ten 90-minute sessions . For the current study using a variable length approach, participants may complete up to 24 sessions. Based on emotional processing theory PE addresses trauma-related avoidance of thoughts, behaviors, and situations, as well as unhelpful beliefs about oneself, others, and the world that were learned as a result of trauma.

  • Cognitive Processing Therapy

    Behavioral

    CPT is a 12-session, cognitive behavioral PTSD treatment typically delivered in 60-minute sessions that can be personalized to include fewer or additional sessions. For the current study using a variable length approach, participants may complete up to 24 sessions. CPT is based in cognitive theory and posits that impeded recovery following trauma occurs due to unhelpful and unrealistic beliefs that may develop after trauma, leading to chronic anger, guilt, shame, and avoidance of trauma reminders. During CPT, patients learn about PTSD symptoms, impeded recovery and cognitive theory, and the connection between trauma-based thoughts and feelings.

  • Written Exposure Therapy

    Behavioral

    WET is a cognitive behavioral therapy for PTSD that typically consists of 5 weekly 50-minute sessions. For the current study using a variable length approach, participants may complete up to 7 sessions. WET is based on an extinction and emotional processing treatment model. First, patients learn about PTSD and the role of avoidance in maintaining PTSD symptoms. Next, patients are guided to write about their trauma for 30 minutes and afterwards, the therapist briefly checks in with the patient. This procedure is followed for the next 4 sessions, with guidance to first write about the trauma, and in later sessions to write about consequences of the trauma and the patient's current meaning of their lives. The goals of WET are to assist the patient in emotionally processing the event and reduce avoidance of trauma-related thoughts and memories, which facilities recovery.

  • Shared Decision Making (SHARE)

    Other intervention

    The study will use the SHARE Approach to facilitate treatment planning and decision-making. SHARE stands for: 1. Seek the patient's participation 2. Help the patient explore and compare treatment options 3. Assess the patient's values and preferences 4. Reach a decision with the patient 5. Evaluate the patient's decision The Shared Decision Making Patient Preference Checklist will be used to determine the participant's preference for type of treatment, frequency of treatment sessions, and treatment delivery modality. Step 5 also includes following up with the patient and making changes if something it not working well for the patient.

Treatment groups

200 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: Prolonged Exposure (PE) Therapy MassedExperimental treatment 2 interventions
Group B: Prolonged Exposure (PE) SpacedExperimental treatment 2 interventions
Group C: Cognitive Processing Therapy (CPT) MassedExperimental treatment 2 interventions
Group D: Cognitive Processing Therapy (CPT) spacedExperimental treatment 2 interventions
Group E: Written Exposure Therapy (WET) MassedExperimental treatment 2 interventions
Group F: Written Exposure Therapy (WET) SpacedExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Completion of treatment initiation

Percentage of participants initiate and complete at least one session of evidence-based Posttraumatic Stress Disorder (PTSD) treatment

Time frame
Baseline to Treatment Session 1 (approximately 2 weeks)
2

Completion of all Treatment sessions

The percentage of participants who complete all manualized protocol sessions (i.e., 10 PE sessions, 12 CPT sessions, or 5 WET sessions) or (2) complete treatment early because they have achieved their treatment goals. This will be defined as achieving a 10 point reduction in on the PCL-5 and scoring below the diagnostic cutoff (a PCL- 5 score of ≤ 30), as well as the therapist and patient agreeing that treatment relevant goals have been met.

Time frame
Baseline to Posttreatment (between 2 months and 7 months, depending on treatment selected and speed of progress)
3

Preference for type of treatment

Measured on a Likert Scale from 0= no preference to 10= extremely high preference

Time frame
Measured at Pre-Treatment Shared Decision-Making Session
4

Posttraumatic Stress Disorder Checklist (PCL-5)

The PCL-5 is a 20-item self-report measure, selected for its dimensional sensitivity, with higher scores reflecting greater PTSD severity. Scoring is based on how much the patient has been bothered by the symptoms in the past month on a scale from "0 = not at all" to "4 = extremely. Scores range from 0-80 with a higher score indicating more severe PTSD.

Time frame
Baseline to 1 month follow up assessment (between 2 months and 7 months, depending on treatment selected and speed of progress)

Secondary outcomes

1

Brief Inventory of Psycho-social Functioning

7-item self-report instrument measuring respondents' level of functioning in seven life domains: romantic relationship, relationship with children, family relationships, friendships and socializing, work, training and education, and activities of daily living. Respondents indicate the degree to which they had trouble in the last 30 days in each area on a 7-point scale ranging from 0 ("Not at all") to 6 ("Very much"). Scores range from 0-42 with a higher score indicating better level of psycho-social function.

Time frame
Baseline to 1 month follow up assessment (between 2 months and 7 months, depending on treatment selected and speed of progress)
2

Patient Health Questionnaire 9 (PHQ-9)

9 items that assess both affective and somatic symptoms related to depression and depressive disorders; these 9 items correspond to the diagnostic criteria for Major Depressive Disorder. Respondents rate the frequency with which they have been bothered by depressive symptoms within the past two weeks on a scale ranging from 0 ("not at all") to 3 ("nearly every day"). Scores on all items are summed to obtain a total severity score between 0-27. Scores reflect no significant depressive symptoms (0-4), mild depressive symptoms (5-9), moderate depressive symptoms (10-14), moderately severe depressive symptoms (15-19), and severe depressive symptoms (\>19)

Time frame
Baseline to 1 month follow up assessment (between 2 months and 7 months, depending on treatment selected and speed of progress)
3

Generalized Anxiety Disorder 7 (GAD-7)

This is a 7-item measure that asks participants to rate the frequency with which they have been bothered by anxiety symptoms within the past two weeks on a scale ranging from 0 ("not at all") to 3 ("nearly every day"). Scores on all items are summed to obtain a total severity score between 0-21. Scores reflect no significant anxiety symptoms (0-4), mild anxiety symptoms (5-9), moderate anxiety symptoms (10-14), and severe anxiety symptoms (\>15).

Time frame
Baseline to 1 month follow up assessment (between 2 months and 7 months, depending on treatment selected and speed of progress)
4

Depressive Symptom Index - Suicidality Subscale (DSI-SS)

The DSI-SS is a 4-item self-report measure of suicidal ideation that focuses on ideation, plans, perceived control over ideation, and impulses for suicide occurring within the past two weeks. Scores on each item range from 0 to 3, with a total possible score from 0-12 with higher scores reflecting greater severity of suicidal ideation.

Time frame
Baseline to 1 month follow up assessment (between 2 months and 7 months, depending on treatment selected and speed of progress)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.